A detailed history of Royal Bank Of Canada transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 252,910 shares of NBIX stock, worth $31.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
252,910
Previous 165,429 52.88%
Holding current value
$31.2 Million
Previous $22.8 Million 27.85%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $10 Million - $13.4 Million
87,481 Added 52.88%
252,910 $29.1 Million
Q2 2024

Nov 06, 2024

SELL
$130.86 - $143.19 $261,458 - $286,093
-1,998 Reduced 1.19%
165,429 $22.8 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $640,297 - $700,628
4,893 Added 3.01%
167,427 $23 Million
Q1 2024

Nov 05, 2024

SELL
$130.4 - $143.74 $3.71 Million - $4.09 Million
-28,453 Reduced 16.99%
138,974 $19.2 Million
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $5.21 Million - $5.75 Million
39,987 Added 32.63%
162,534 $22.4 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $7.89 Million - $9.88 Million
74,419 Added 154.63%
122,547 $16.1 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $397,986 - $495,684
4,233 Added 9.64%
48,128 $5.41 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $6.61 Million - $7.74 Million
-73,828 Reduced 62.71%
43,895 $4.14 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $341,525 - $446,439
-3,629 Reduced 2.99%
117,723 $11.9 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $795,490 - $947,105
7,454 Added 6.54%
121,352 $14.5 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $549,695 - $643,949
5,973 Added 5.53%
113,898 $12.1 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $2.77 Million - $3.66 Million
36,590 Added 51.29%
107,925 $10.5 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $710,734 - $930,086
9,810 Added 15.94%
71,335 $6.69 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $141,538 - $188,752
1,777 Added 2.97%
61,525 $5.24 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $666,257 - $765,600
-7,731 Reduced 11.46%
59,748 $5.73 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $6.03 Million - $6.9 Million
67,479 New
67,479 $6.57 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.